Rational treatment for vulvovaginal candidiasis caused by resistant Candida species
<p> <b>G.B. Dikke</b><br> </p> <p> <b>F.I. Inozemtsev Academy of Medical Education, St. Petersburg, Russian Federation</b> </p> <p> <i>In recent decade, growing incidence (24-29%) of vulvovaginal candidiasis caused by Candida non-albi...
Saved in:
Main Author: | |
---|---|
Format: | Book |
Published: |
LCC «Medicine-Inform»,
2019-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_61b9c9e80fe04d7985e92d821cc2e0a1 | ||
042 | |a dc | ||
100 | 1 | 0 | |a G.B. Dikke |e author |
245 | 0 | 0 | |a Rational treatment for vulvovaginal candidiasis caused by resistant Candida species |
260 | |b LCC «Medicine-Inform», |c 2019-09-01T00:00:00Z. | ||
500 | |a 2618-8430 | ||
500 | |a 2686-7184 | ||
520 | |a <p> <b>G.B. Dikke</b><br> </p> <p> <b>F.I. Inozemtsev Academy of Medical Education, St. Petersburg, Russian Federation</b> </p> <p> <i>In recent decade, growing incidence (24-29%) of vulvovaginal candidiasis caused by Candida non-albicans is reported. Candida species are characterized by reduced (on average, 2-fold) sensitivity to azoles and cross-resistance. Differential treatment strategy choice for vulvovaginal candidiasis depends on clinical variant (acute or recurrent) and etiological agent (identification of Candida species by culture). In vulvovaginal candidiasis caused by Candida non-albicans or azole-resistant Candida albicans (including vulvovaginal candidiasis in pregnant and nursing women), polyene antibiotic (i.e., natamycin) should be prescribed. The efficacy of the treatment of acute non-complicated vulvovaginal candidiasis with vaginal natamycin (100 mg daily) is 67-85% for 3 day-treatment and 86-95% for 6-day treatment. Natamycin (100 mg vaginally for 6 to 12 days) is first-line therapy for recurrent vulvovaginal candidiasis caused by Candida non-albicans. Treatment efficacy for a certain episode is 88-94%. Proceeding with treatment for six months (100 mg weekly) prevents recurrences in 98% of women. In pregnant women, natamycin results in clinical recovery during the whole pregnancy and promotes decreased rate of pregnancy complications.</i> </p> <p> <i><b>Keywords</b>: vulvovaginal candidiasis, Candida albicans, Candida non-albicans, biofilm, recurrence, pregnancy, antifungal treatment, natamycin, Primafungin.</i> </p> <p> <i><b>For citation: </b>Dikke G.B. Rational treatment for vulvovaginal candidiasis caused by resistant Candida species. Russian Journal of Woman and Child Health. 2019;2(3):187-193.</i> </p> <i><br> </i><br> | ||
546 | |a RU | ||
690 | |a Pediatrics | ||
690 | |a RJ1-570 | ||
690 | |a Gynecology and obstetrics | ||
690 | |a RG1-991 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n РМЖ. Мать и дитя, Vol 2, Iss 3 (2019) | |
787 | 0 | |n http://wchjournal.com/upload/iblock/14b/14b2d8fa6dfe9fc193302c9dd4bfa855.pdf | |
787 | 0 | |n https://doaj.org/toc/2618-8430 | |
787 | 0 | |n https://doaj.org/toc/2686-7184 | |
856 | 4 | 1 | |u https://doaj.org/article/61b9c9e80fe04d7985e92d821cc2e0a1 |z Connect to this object online. |